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Abstract
The repercussions of secondary hyperparathyroidism on the nutri-
tional status of chronic renal failure patients have not been well
established. Therefore, the aim of this study was to compare the
nutritional indices of hemodialysis patients with and without second-
ary hyperparathyroidism. Sixteen hemodialysis patients with serum
parathyroid hormone (PTH) levels higher than 420 pg/ml (hyperpara-
thyroidism group) were matched for gender, age and length of dialysis
treatment to 16 patients with serum PTH between 64 and 290 pg/ml
(control group). The following parameters were assessed: anthropo-
metric indices (body mass index, skinfold thickness, midarm muscle
circumference and body fat), 4-day food diaries, protein catabolic rate,
biochemical indices (blood urea nitrogen, serum creatinine, albumin,
ionized calcium, inorganic phosphorus, serum alkaline phosphatase,
PTH, pH and HCO3) and dialysis efficiency. We did not observe
differences in the anthropometric indices between the two groups.
Only calcium intake was significantly different between groups (307.9
mg/day for the hyperparathyroidism group vs 475.8 mg/day for the
control group). Protein catabolic rate tended to be higher in the
hyperparathyroidism group compared to the control group (1.3 vs 0.9
g kg-1 day-1; P = 0.08). Except for blood urea nitrogen (86.4 vs 75.7 mg/
dl), alkaline phosphatase (175 vs 65 U/l) and PTH (898 vs 155 pg/ml),
no other differences were found between groups in the biochemical
indices studied. PTH was directly correlated with protein catabolic
rate (r = 0.61; P<0.05) and length of dialysis (r = 0.53; P<0.05) only in
the hyperparathyroidism group. Considering the indices used, we
could not demonstrate the deleterious effect of high PTH levels on the
nutritional status of hemodialysis patients. Indirect evidence, how-
ever, suggests an action of PTH on protein metabolism.
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Introduction
Malnutrition is present to some extent in
approximately 40% of chronic renal failure
(CRF) patients on maintenance hemodialy-
sis (1,2). Several markers of malnutrition
such as low body mass index and low serum
albumin have been associated with high mor-
bidity and mortality rates in this group of
patients (3,4). Malnutrition in these patients
is considered to be due to anorexia with low
food intake (5-7), to the loss of nutrients and
catabolism during the dialysis procedure
(8,9), intercurrent illnesses (10), metabolic
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acidosis (11), glucose intolerance (12), in-
creased cytokine levels (13), and other hor-
monal derangements (14). Among these last
disturbances, high parathyroid hormone
(PTH) levels, frequently observed in CRF
patients, may be implicated in the nutritional
abnormalities found in these patients. In fact,
it has been observed that patients with pri-
mary hyperparathyroidism may show evi-
dence of weight loss, weakness and muscle
atrophy and negative nitrogen balance (15-
17). It is not clear, however, to what extent
these findings may be caused by either a
direct deleterious effect of PTH on protein
metabolism (18) or an indirect effect causing
fatigue, anorexia, neuropsychiatric distur-
bances, myopathy or bone disease (15,16).
Few studies have analyzed the effects of
high PTH levels on protein metabolism. Ex-
perimental work on muscle tissue suggests
that PTH induces an increase in protein ca-
tabolism (18), although this finding has not
been confirmed by other investigators (19).
Conversely, the effects of secondary hyper-
parathyroidism on the nutritional status of
chronic hemodialysis patients have not been
studied. Thus, the aim of this study was to
compare the nutritional status of hemodialy-
sis CRF patients with and without secondary
hyperparathyroidism.
Material and Methods
Patients
The patients studied were selected from
189 patients dialyzed at the outpatient Dialy-
sis Unit, Nephrology Division, Federal Uni-
versity of Sªo Paulo (UNIFESP). Sixteen
patients with secondary hyperparathyroid-
ism on chronic hemodialysis were selected
for this study. They were included in the
study if they had serum PTH concentration
higher than 420 pg/ml (hyperparathyroidism
group; N = 16). They were matched for
gender, age and length on dialysis to a group
of patients with serum PTH concentration
between 64 and 290 pg/ml (control group; N
= 16). According to some studies, normal
bone metabolism in chronic renal failure has
been associated with PTH levels up to 4
times the upper normal limit (20,21). None
of the patients in the control group had ever
been treated for secondary hyperparathy-
roidism. Exclusion criteria for both groups
were age lower than 18 years, diabetes mel-
litus, autoimmune, malignant or infectious
diseases, chronic alcoholism, patients sub-
mitted to parathyroidectomy or to immobili-
zation, and those with kidney transplanta-
tion failure in the last 6 months. All subjects
were instructed to eat approximately 30 to
35 kcal kg desirable body weight-1 day-1 and
to eat 1.0 to 1.2 g kg desirable body weight-1
day-1 of protein. All patients studied were
dialyzed 3 times a week for 4 h with a
Cuprophanfi membrane.
The study was approved by the Ethics
Committee of UNIFESP and informed con-
sent was obtained from each subject.
Study protocol
After selection, we first interviewed the
patients in order to obtain informed consent,
to collect blood samples for biochemical
analysis and to instruct them to fill out the
food diaries. Anthropometric data and the
food diaries were obtained one week later
and after a regular hemodialysis session.
Nutritional assessment
Anthropometric measurements included
body weight, height, tricipital skinfold (TSF),
biceps, subscapular and suprailiac skinfold
thickness, and midarm muscle circumfer-
ence (MAMC). Body mass index (BMI) was
calculated as body weight divided by squared
height (22). Skinfold thicknesses were meas-
ured using Lange calipers (Cambridge In-
strument, Cambridge, MD, USA). These
measurements were performed by the same
observer on the side of the body opposite to
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that of the vascular access for hemodialysis.
Percentage of fat was estimated from the
sum of four skinfold thicknesses according
to the equations of Durnin and Wormersley
(23). MAMC was calculated using the for-
mula (24): MAMC = arm circumference -
(0.314 x TSF). Percent standard TSF and
MAMC were obtained using the National
Health and Nutrition Examination Survey
(NHANES) percentile distribution tables a-
dapted by Frisancho (24). Dietary intake was
evaluated from 4-day food diaries that in-
cluded 1 dialysis day, 2 days without the
treatment and 1 weekend day. Energy and
protein intakes were expressed in relation to
desirable body weight. Energy and nutrients
were calculated using a computer software
developed at UNIFESP which contains the
US Department of Agriculture tables as the
nutrient data base (25). Protein catabolic rate
was determined according to the formula of
Sargent and Gotch (26).
Biochemical parameters
Blood samples were drawn from the pa-
tients under fasting conditions immediately
before the dialysis session for determination
of ionized calcium, phosphorus, alkaline
phosphatase, PTH, pH, bicarbonate, albu-
min, urea nitrogen, and serum creatinine.
Phosphorus, creatinine and urea nitrogen
were determined with a standard autoana-
lyzer. Ionized calcium was determined using
a calcium-specific electrode (AVL 9140,
Medical Instruments AG, Schaffhausen,
Switzerland; normal range = 1.12 to 1.32
mmol/l). Total alkaline phosphatase was de-
termined using a commercial enzyme linked
immunoassay kit (ELISA; normal values
range from 40 to 190 U/l). PTH was deter-
mined using an immunofluorimetric assay
which detects the intact PTH molecule with
normal values ranging from 10 to 70 pg/ml
(27). Bicarbonate and pH were measured
using a specific electrode (normal value range
= 24 to 28 mEq/l and 7.32 to 7.42, respec-
tively). The colorimetric method was used to
determine serum albumin. Hemodialysis ef-
ficiency was assessed by calculating Kt/V
(28).
Statistical analysis
All data are expressed as median and
range. The Mann-Whitney U-test was used
to compare patients with and without sec-
ondary hyperparathyroidism. The Spearman
rank correlation coefficient was calculated
to test quantitative associations between two
variables. The Fisher test was used do com-
pare the frequency of malnutrition between
the two groups. Statistical significance was
defined as P<0.05.
Results
The clinical and biochemical character-
istics of the patients are shown in Table 1.
There was a predominance of males and the
patients were relatively young. The median
length of dialysis was relatively short. In-
Table 1 - Clinical and biochemical characterization of the patients.
Data are reported as median and range (in parentheses). H = Hypertension, CG =
chronic glomerulonephritis, PKD = polycystic kidney disease, BUN = blood urea
nitrogen, PTH = parathyroid hormone, ND = not determined. *P<0.05 vs control group
(Mann-Whitney U-test).
Hyperparathyroidism Control
 group (N = 16) group (N = 16)
Gender (male/female) 10/6 10/6
Age (years) 46.5 (20-80) 47.0 (20-81)
Length of dialysis (months) 17.5 (7-289) 21.5 (12-132)
Etiology H = 4, CG = 4, PKD = 2 H = 9, CG = 2
ND = 5, Others = 1 Others = 5
BUN (mg/dl) 86.4 (60.2-110.2) 75.7 (50.4-110.2)*
Serum creatinine (mg/dl) 13.5 (6.8-17.0) 13.6 (6.5-16.3)
Dialysis efficiency (Kt/V) 1.4 (0.4-1.7) 1.2 (0.8-1.6)
pH 7.20 (7.10-7.30) 7.25 (7.10-7.40)
Serum bicarbonate (mEq/l) 17.1 (11.7-28.7) 17.3 (13.5-26.2)
Serum albumin (g/dl) 4.2 (3.3-5.3) 4.0 (3.4-4.9)
Serum ionized calcium (mmol/l) 1.20 (1.10-1.60) 1.20 (1.10-1.30)
Serum inorganic phosphorus (mg/dl) 5.5 (1.7-9.1) 6.0 (1.7-9.5)
Serum alkaline phosphatase (U/l) 175.0 (51.0-1095.0) 65.0 (31.0-215.0)*
Serum PTH (pg/ml) 898.0 (439.0-2120.0) 155.0 (64.0-288.0)*
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deed, 25% of the patients in the hyperpara-
thyroidism group and 19% of the patients in
the control group had been on chronic hemo-
dialysis for less than 12 months. Patients
with hyperparathyroidism had significantly
higher levels of blood urea nitrogen (BUN)
as compared with the control group. Both
groups had metabolic acidosis. In fact, 9
patients (56%) in the hyperparathyroidism
group and 8 (50%) in the control group had
venous blood pH below 7.32. The median
serum albumin levels were within the nor-
mal range in both groups and only one pa-
tient in each group had a serum albumin
level of less than 3.5 g/dl. The Kt/V values
were similar and adequate in both groups of
patients. Median ionized calcium value was
normal, with only one patient presenting
hypercalcemia (iCa2+ = 1.60 mmol/l). Eleven
patients (69%) in each group showed serum
phosphorus levels higher than 4.5 mg/dl. As
expected, PTH values were significantly
higher in the hyperparathyroidism group.
As can be seen in Table 2, we did not find
any significant difference in the anthropo-
metric indices between groups. Twelve pa-
tients (75%) with secondary hyperparathy-
roidism and 10 patients (62.5%) in the con-
trol group had BMI between 18.5 and 25.0
kg/m2. The median standard percent of TSF
was 76.7 and 77.1%, respectively. Only 3
patients (18.8%) with secondary hyperpara-
thyroidism and 1 (6.2%) in the control group
showed signs of malnutrition with TSF val-
ues below the 5th percentile. These frequen-
cies were not different between groups. The
median percent standard values of the
MAMC were 92.0% in the hyperparathy-
roidism group and 89.5% in the control group.
However, 5 patients (31.3%) with secondary
hyperparathyroidism and 6 patients (37.5%)
in the control group showed MAMC values
below the 5th percentile. Considering both
parameters (TSF and MAMC), only 2 pa-
tients in the hyperparathyroidism group and
1 patient in the control group had values
below the 5th percentile.
Table 2 - Anthropometric indices.
Data are reported as median and range (in parentheses). BMI = Body mass index, TSF
= tricipital skinfold thickness, MAMC = midarm muscle circumference, LBM = lean
body mass.
Hyperparathyroidism group (N = 16) Control group (N = 16)
Body weight (kg) 61.4 (50.0-81.1) 63.1 (50.0-78.6)
BMI (kg/m2) 24.0 (18.6-30.7) 22.1 (18.9-30.6)
TSF (standard %) 76.7 (41.7-136.4) 77.1 (37.5-167.0)
MAMC (standard %) 92.0 (70.0-115.4) 89.5 (68.4-122.0)
Body fat (%) 24.7 (11.2-40.0) 22.0 (9.8-37.7)
LBM (kg) 46.8 (36.4-60.2) 49.9 (34.0-64.0)
Table 3 - Dietary intake and protein catabolic rate.
Data are reported as median and range (in parentheses). +N = 12. *P<0.05 vs control
group (Mann-Whitney U-test).
Hyperparathyroidism group (N = 16) Control group (N = 16)
Energy (kcal kg-1 day-1) 25.4 (12.9-59.5) 23.3 (20.0-61.6)
Protein (g kg-1 day-1) 0.95 (0.5-2.3) 0.90 (0.6-2.8)
Calcium (mg/day) 307.9 (109.8-1280.0) 475.8 (226.8-1300.4)*
Phosphorus (mg/day) 639.7 (387.7-2206.4) 816.4 (426.3-1724.8)
Protein catabolic rate 1.3 (0.7-1.9) 0.90 (0.5-1.8)
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Figure 1 - Protein catabolic rate versus parathyroid hormone (PTH) in the hyperparathyroid-
ism group.
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The analysis of the food diaries showed
that the median energy and protein intakes
were below the recommendations and were
similar in both groups, averaging 23 to 25
kcal kg-1 day-1 (Table 3), but calcium intake
was significantly lower in the hyperparathy-
roidism group. There was a trend to a higher
phosphorus intake in the patients in the con-
trol group; protein catabolic rate was higher
in patients in the hyperparathyroidism group
but the difference did not reach statistical
significance (1.3 vs 0.9 g kg-1 day-1; P =
0.08). No correlations were found between
PTH values and anthropometric indices in
the population as a whole or in the hyper-
parathyroidism group. However, in the latter
group PTH was significantly correlated with
protein catabolic rate (N = 12; r = 0.61;
P<0.05; Figure 1). Furthermore, PTH levels
were correlated with length of dialysis (N =
16; r = 0.53; P<0.05) only in the hyperpara-
thyroidism group.
Discussion
In the present study we tested the hypo-
thesis that high PTH levels could have del-
eterious effects on the nutritional status of
patients with secondary hyperparathyroid-
ism. However, when comparing the hyper-
parathyroidism patients to their respective
controls, we did not observe any significant
difference in any of the nutritional indices
studied. In fact, although they were matched
only for age, gender and length of dialysis,
both groups of patients showed similar val-
ues of BMI, TSF, MAMC, body fat, lean
body mass and serum albumin.
The energy intake of our patients, of 23 to
25 kcal kg-1 day-1, was far below the recom-
mended amount for patients on hemodialy-
sis (29), as systematically observed in many
studies (1,6,7). Anorexia of chronic renal
failure may be implicated in this low energy
intake and may be related to the malnutrition
of these patients (30). It is worthy of note
that, even with low energy consumption,
only 2 patients in the hyperparathyroidism
group and 1 patient in the control group were
considered malnourished. Probably, in both
groups the deleterious effects of such a low
energy intake on nutritional status was not
observed because most of the patients had
been on dialysis for a short period of time. In
fact, the hemodialysis procedure may cause
malnutrition either by inducing losses of
nutrients or by promoting inflammatory re-
sponses through blood-membrane interac-
tions (8,9). Another possibility is under-
reporting and/or systematic errors in the esti-
mation of food consumption by the patients
as observed by some authors (31).
PTH has long been considered a uremic
toxin, with many deleterious cellular and
metabolic effects (32). It increases bone turn-
over (33) and induces neuropathy (34), my-
opathy (15,16), cardiac hypertrophy (35),
hyperlipidemia (36), carbohydrate intoler-
ance (12) and immune dysfunction (37). Al-
though specific studies are lacking, such
conditions could influence the nutritional
status of uremic patients with secondary hy-
perparathyroidism. Garber (18) demonstrated
in vitro that high PTH levels enhanced muscle
proteolysis and increased the release of ala-
nine and glutamine. This effect, however,
was observed only in normal rats. On the
other hand, Wassner and Li (19) did not
observe any change in protein metabolism
when muscle of normal rats was perfused
with PTH. In humans, it was observed that
patients with primary hyperparathyroidism
have a negative nitrogen balance that is cor-
rected after parathyroidectomy (17). In the
present study, according to the anthropomet-
ric indices, we did not observe any interfer-
ence of secondary hyperparathyroidism with
the nutritional status of the patients. How-
ever, there was some indirect evidence sug-
gesting that PTH could have exerted its ac-
tion causing some degree of protein catabo-
lism. In fact, BUN was significantly higher
and protein catabolic rate tended to be more
elevated in patients with hyperparathyroid-
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ism, despite the similar protein intake ob-
served in both groups. Moreover, PTH was
directly correlated with protein catabolic rate
in the hyperparathyroidism group, suggest-
ing an action of PTH in increasing protein
catabolism. On the other hand, we must
consider that this indirect evidence of pro-
tein catabolism (high BUN and protein cata-
bolic rate values) could also be the result of
a higher protein intake in the hyperparathy-
roidism group which, however, was not de-
tected in the food diaries. If that effect did
occur, the anthropometric indices used to
estimate the muscle mass of these patients
may have not been sensitive enough to de-
tect such interference. Alternatively, it is
also possible that the duration of secondary
hyperparathyroidism was too short to ad-
versely affect muscle mass as these patients
had been on dialysis for a relatively short
period of time. Accordingly, PTH was sig-
nificantly correlated with the length of dialy-
sis treatment in the patients with hyperpara-
thyroidism.
Finally, despite the reasonable strength
of this study protocol, the number of patients
studied does not permit the characterization
of a definite effect of secondary hyperpara-
thyroidism on the nutritional status of hemo-
dialysis patients. Furthermore, as indicated
by the relationship between time on dialysis
and degree of hyperparathyroidism, a study
protocol including the duration of hyper-
parathyroidism would better analyze its in-
fluence on nutritional status. Since there was
indirect evidence that PTH could interfere
with protein catabolism, other studies are
necessary to elucidate this interaction.
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